Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Joint Bone Spine ; 91(4): 105703, 2024 Feb 07.
Article in English | MEDLINE | ID: mdl-38336272

ABSTRACT

OBJECTIVE: Septic arthritis of the Facet Joints (SAFJ) is a rare condition. Little data has been published on the subject. We aimed to describe the clinical, biological and imagery presentations, as well as the course of this rare infection. METHODS: We included patients hospitalized between January 1st, 2016 and December 31th, 2019, in the Departments of Infectious Diseases or Rheumatology in 5 French centres in the CRIOGO network. We defined septic arthritis according to Newman's criteria and facet joint arthritis using imagery. RESULTS: Sixty-five patients were included, predominantly males (64.6%), with a mean age of 68.1 years. The mean time to diagnosis was 25.0 days. The principal symptoms at diagnosis were acute back pain (95.2%) and fever (76.9%). Neurological symptoms were present for 60.7% of the patients, including 16.4% motor deficit or cauda equina syndrome. SAFJ was located on the lumbosacral spine (73.4%) and was rarely multifocal (4.7%). Bacteriological identification was performed by blood cultures in 84.4% of the cases, and the pathogen was mainly Staphylococcus aureus (49.2%). Infective endocarditis was present for 26.9% of patients assessed by echocardiography. On MRI, soft tissue abscess or inflammation, epiduritis and epidural abscess were present in 87.1%, 66.7% and 33.9% of cases, and the pathogen was significantly more frequently Staphylococcus aureus. Mortality reached 9.2%, 18.5% and 23% at one, two, and three years respectively. CONCLUSION: SAFJ is a rare but severe disease. Microbiological diagnosis is primarily made on blood cultures, and S. Aureus was the main pathogen. Our results highlight the fact that SAFJ is associated with high morbidity and mortality, and with infective endocarditis.

2.
Ann Intensive Care ; 13(1): 13, 2023 Mar 03.
Article in English | MEDLINE | ID: mdl-36867272

ABSTRACT

BACKGROUND: Unique blood culture (UBC) has been proposed to limit the number of venipuncture and to decrease the risk of BC contaminations (BCC) without affecting their yield. We hypothesized that a multi-faceted program based on UBC in the ICU may reduce the rate of contaminants with a similar performance for bloodstream infections (BSI) identification. METHODS: In a before and after design, we compared the proportion of BSI and BCC. A first 3-year period with multi-sampling (MS) strategy followed by a 4-month washout period, where staff received education and training for using UBC, and a 32-month period, where UBC was routinely used, while education and feedback were maintained. During the UBC period, a large volume of blood (40 mL) was sampled through a unique venipuncture with additional BC collections discouraged for 48 h. RESULTS: Of the 4,491 patients included (35% female patients, mean age 62 years) 17,466 BC were collected. The mean volume of blood per bottle collected increased from 2.8 ± 1.8 mL to 8.2 ± 3.9 mL between the MS and UBC periods, P < 0.01. A 59.6% reduction (95% CI 56.7-62.3; P < 0.001) of BC bottles collected per week was observed between the MS and UBC periods. The rate of BCC per patient decreased between the two periods from 11.2% to 3.8% (73.4% reduction; P < 0.001) for the MS and UBC periods, P < 0.001. Meanwhile, the rate of BSI per patient remained stable at 13.2% and 13.2% for the MS and UBC periods, P = 0.98. CONCLUSIONS: In ICU patients, a strategy based on UBC reduces the contamination rate of cultures without affecting their yield.

3.
Maturitas ; 149: 34-36, 2021 Jul.
Article in English | MEDLINE | ID: mdl-34134888

ABSTRACT

Nosocomial COVID-19 in older patients has a high mortality rate. We describe an outbreak of COVID-19 in a geriatric acute care unit (GACU) in March/April 2020 and the lessons learnt regarding prevention. Thirty-six patients were diagnosed with COVID-19 during that 2-month period, in France's "first wave" of SARS-CoV-2 infections. Thirty (83.3%) were considered nosocomial. Attributable mortality reached 33.3% in these patients. Healthcare workers (HCW) were not spared, with an overall attack rate of 36.8%, but the rate was especially high among nurse assistants (68.2%). Repeated testing, single rooms, hand hygiene, and good use of personal protective equipment are paramount in GACUs to prevent in-hospital COVID-19 outbreaks.


Subject(s)
COVID-19/transmission , Cross Infection/virology , Health Personnel/standards , Hospitals/standards , Infection Control/organization & administration , Personal Protective Equipment/statistics & numerical data , SARS-CoV-2/isolation & purification , Aged, 80 and over , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19/virology , Cross Infection/epidemiology , Cross Infection/prevention & control , Cross Infection/transmission , Female , Humans , Infection Control/standards , Male
4.
Eur J Clin Microbiol Infect Dis ; 39(11): 2185-2194, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32519215

ABSTRACT

To increase the knowledge about S. capitis in the neonatal setting, we conducted a nationwide 3-month survey in 38 neonatal intensive care units (NICUs) covering 56.6% of French NICU beds. We demonstrated 14.2% of S. capitis BSI (S.capBSI) among nosocomial BSIs. S.capBSI incidence rate was 0.59 per 1000 patient-days. A total of 55.0% of the S.capBSIs were late onset catheter-related BSIs. The S. capitis strains infected preterm babies (median gestational age 26 weeks, median birth weight 855 g). They were resistant to methicillin and aminoglycosides and belonged to the NRCS-A clone. Evolution was favorable in all but one case, following vancomycin treatment.


Subject(s)
Sepsis/epidemiology , Staphylococcal Infections/epidemiology , Staphylococcus capitis/isolation & purification , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Catheter-Related Infections/drug therapy , Catheter-Related Infections/epidemiology , Catheter-Related Infections/etiology , Drug Resistance, Multiple, Bacterial , Female , France/epidemiology , Humans , Infant, Newborn , Infant, Premature , Intensive Care Units, Neonatal , Male , Sepsis/drug therapy , Sepsis/etiology , Staphylococcal Infections/drug therapy , Staphylococcal Infections/etiology , Staphylococcus capitis/drug effects
5.
Int J Infect Dis ; 85: 175-181, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31212103

ABSTRACT

BACKGROUND: The optimal treatment of streptococcal prosthetic joint infections (PJIs) is unclear. METHODS: A cohort of streptococcal PJIs was reviewed retrospectively in seven reference centers for the management of complex bone and joint infections, covering the period January 1, 2010 to December 31, 2012. RESULTS: Seventy patients with monomicrobial infections were included: 47 had infections of total hip arthroplasty and 23 had infections of total knee arthroplasty. The median age was 77 years (interquartile range (IQR) 69-83 years), the median Charlson comorbidity score was 4 (IQR 3-6), and 15.6% (n=11) had diabetes. The most commonly identified streptococcal species were Streptococcus agalactiae and Streptococcus dysgalactiae (38.6% (n=27) and 17.1% (n=12), respectively). Debridement, antibiotics and implant retention (DAIR) was performed after a median time of 7 days (IQR 3-8 days), with polyethylene exchange (PE) in 21% of cases. After a minimum follow-up of 2 years, 27% of patients had relapsed, corresponding to 51.4% of DAIR treatment cases and 0% of one-stage (n=15) or two-stage (n=17) exchange strategy cases. Rifampicin or levofloxacin in combination therapy was not associated with a better outcome (adjusted p= 0.99). S. agalactiae species and DAIR treatment were associated with a higher risk of failure. On multivariate analysis, only DAIR treatment and S. agalactiae were independent factors of relapse. Compared to DAIR without PE, DAIR with PE was only associated with a trend towards a benefit (odds ratio 0.33, 95% confidence interval 0.06-1.96; adjusted p= 0.44). CONCLUSIONS: Streptococcal PJIs managed with DAIR have a poor prognosis and S. agalactiae seems to be an independent factor of treatment failure.


Subject(s)
Bone Diseases/therapy , Joint Diseases/therapy , Prosthesis-Related Infections/therapy , Streptococcal Infections/therapy , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Bone Diseases/drug therapy , Bone Diseases/microbiology , Bone Diseases/surgery , Combined Modality Therapy , Debridement , Drug Therapy, Combination , Female , Hip Prosthesis/adverse effects , Humans , Joint Diseases/drug therapy , Joint Diseases/microbiology , Joint Diseases/surgery , Knee Prosthesis/adverse effects , Levofloxacin/therapeutic use , Male , Prognosis , Prosthesis-Related Infections/drug therapy , Prosthesis-Related Infections/microbiology , Prosthesis-Related Infections/surgery , Recurrence , Retrospective Studies , Rifampin/therapeutic use , Streptococcal Infections/drug therapy , Streptococcal Infections/microbiology , Streptococcal Infections/surgery , Streptococcus/isolation & purification , Streptococcus agalactiae/isolation & purification , Treatment Failure , Treatment Outcome
8.
Rev Prat ; 64(8): 1079-85, 2014 Oct.
Article in French | MEDLINE | ID: mdl-25510130

ABSTRACT

In 2014 an antiretroviral treatment should be initiated in any HIV-infected patient, whatever his/her CD4 lymphocyte count. The objectives of antiretroviral treatment are both individual (restoration or preservation of immune functions, decreased morbidity and mortality, decreased chronic systemic inflammation) and collective (decreased risk of HIV sexual transmission). Preferred initial regimens include two nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabine or abacavir/lamivudine) plus a third agent, either a non-nucleoside reverse transcriptase inhibitor (rilpivirine or efavirenz), or a ritonavir-boosted protease inhibitor (atazanavir or darunavir). Alternatively, the third agent may be chosen among integrase inhibitors (raltegravir, dolutegravir, elvitegravir/cobicistat). Immunologic and virologic response to first-line antiretroviral therapy should be monitored closely according to specific criteria and objectives.


Subject(s)
Anti-Retroviral Agents/therapeutic use , HIV Infections/drug therapy , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...